Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Bristol-Myers Squibb42 enrolled

Overview

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

MuraglitazarDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes; * Serum triglyceride concentration \< or = 600 mg/dL; * Body mass index \< or = 37 kg/m2 Exclusion Criteria: * Type 1 diabetes; * History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months; * Congestive heart failure (NYHA Class III and IV); * Uncontrolled hypertension; * Women of Child Bearing Potential * History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease

Locations (2)

Local Institution

San Antonio, Texas, United States

Local Institution

Pisa, Italy

Outcomes

Primary Outcomes

The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.